ZNTL · Zentalis Pharmaceuticals, Inc.

Track ZNTL — free

$3.51 -0.08 (-2.23%) At close · Sep 11

Russell 2000 member Rebalance outlook locked

Market Cap

$252.29M

71.67M

Up next

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

Trailing 12 months

Net income (TTM)

−$139.54M

Trailing 12 months

Revenue growth YoY

-100.0%

Year over year

Operating margin

—

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

-50.8%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$24.78M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

-0.9%

Year over year · fewer shares

Price change (1Y)

+145.9%

Trailing year

Short interest

7.0%

Latest settlement · 5.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Weak Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.60

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg +6%

above

Price vs 50-day avg −18%

below

RSI (14) 37

neutral

MACD trend Negative

52-week position 42%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return −15%

trailing

6-month return +34%

trailing

YTD return +160%

this year

Relative strength +16%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +33 funds added

Insider flow Accumulating

Net +$15.2M over 90 days · 0% sells

Short interest Falling

6.96% of float · ▼ -16.5% MoM · 5.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

113 holders — mid 3-yr range

Squeeze score 58

elevated · 0–100

Fundamentals

Weak

Revenue growth −100%

Y/Y

EPS growth +18%

Y/Y

Free cash flow $-125.2M

Quant / Vol

risk profile

Very High

Volatility 128%

annualized · 1-yr

Max drawdown −47%

past year

ATR 7.4%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral

2 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+6% Bullish

Price vs 50-day avg

−18% Bearish

RSI (14)

37 Neutral

MACD trend

Negative Bearish

52-week position

42% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $4 › 200d $3 — 50d above 200d

Institutional flow Accumulating

+11% holders QoQ · +33 funds added

Insider flow Accumulating

Net +$15.2M over 90 days · 0% sells

Short interest Falling

6.96% of float · ▼ -16.5% MoM · 5.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

113 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $1 Now $4 · 42% Range high $7

vs 200-day avg +6% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
ZNTL Zentalis Pharmaceuticals, Inc. this stock	$252.29M	+160.0%	-100.0%	—	7.0%
VRTX Vertex Pharmaceuticals Inc / Ma	$130.40B	+13.7%	+46.2%	30.0	1.8%
REGN Regeneron Pharmaceuticals, Inc.	$81.67B	+1.2%	+20.8%	19.6	2.5%
ARGX Argenx SE	$61.60B	+17.1%	—	—	2.0%
CSLLY Csl Ltd	$57.41B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

113

% held: 67.0%
Net QoQ: +4.0M sh
Top holder: 5AM Venture Management, L…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

5.0M

Days to cover: 5.1d
Change: -983.0K sh

View

Short Volume

Short vol %

67%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

31.4K

Value: $145.9K
As of: Aug 4, 2026

View

Off-Exchange

Off-exchange %

37.3%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net buying

Net (90d)

+$15.2M

Buyers / Sellers: 1 / 0

Buyers Sellers

View

Financials

Revenue (FY)

Net income (FY): $-137.1M
EPS diluted: $-1.91

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 8, 2026
This year: 18

View

Proposed Sales

Value

$1.4K

Shares: 687
Filed: Feb 11, 2025

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 14, 2026

Last call: Sep 8, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
ZNTL	-14.6%	-15.4%	+34.0%	-6.7%	+160.0%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-13.5%	-13.7%	+16.1%	-6.3%	+147.9%

Key facts CIK 1725160 CUSIP 98943L107 13F (30d) 67 filings 67 filers Visit website Investor relations

ZNTL · Zentalis Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Technicals

Key metrics

Versus peers

At a glance

Performance